Lantheus (NASDAQ:LNTH) Hits New 12-Month High Following Better-Than-Expected Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) shares reached a new 52-week high on Thursday following a better than expected earnings announcement. The stock traded as high as $81.00 and last traded at $71.99, with a volume of 32651 shares traded. The stock had previously closed at $75.89.

The medical equipment provider reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.25. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The company had revenue of $223.80 million for the quarter, compared to the consensus estimate of $204.51 million. During the same quarter in the previous year, the business earned $0.11 earnings per share. The company’s revenue for the quarter was up 121.4% on a year-over-year basis.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. B. Riley assumed coverage on Lantheus in a research report on Monday, May 9th. They issued a “buy” rating and a $91.00 target price on the stock. Truist Financial boosted their price objective on Lantheus from $77.00 to $94.00 in a report on Monday, May 2nd. Finally, SVB Leerink boosted their price objective on Lantheus from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Friday.

Insider Activity at Lantheus

In related news, CEO Mary Anne Heino sold 12,276 shares of the business’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $61.19, for a total value of $751,168.44. Following the sale, the chief executive officer now owns 695,115 shares in the company, valued at approximately $42,534,086.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Lantheus news, CEO Mary Anne Heino sold 12,276 shares of the company’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $61.19, for a total transaction of $751,168.44. Following the sale, the chief executive officer now owns 695,115 shares in the company, valued at approximately $42,534,086.85. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Andrea Sabens sold 386 shares of the company’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $69.12, for a total value of $26,680.32. Following the sale, the chief accounting officer now owns 64,255 shares in the company, valued at approximately $4,441,305.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,798 shares of company stock worth $1,676,307. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Lantheus

Several large investors have recently bought and sold shares of the stock. Financial Gravity Asset Management Inc. purchased a new stake in Lantheus during the 2nd quarter worth about $2,319,000. Nia Impact Advisors LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $1,718,000. Hanseatic Management Services Inc. boosted its position in shares of Lantheus by 7,396.5% during the 2nd quarter. Hanseatic Management Services Inc. now owns 8,621 shares of the medical equipment provider’s stock worth $569,000 after acquiring an additional 8,506 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $730,000. Finally, Convergence Investment Partners LLC acquired a new position in shares of Lantheus during the 2nd quarter worth about $201,000. Hedge funds and other institutional investors own 97.14% of the company’s stock.

Lantheus Trading Up 10.3 %

The company has a 50-day moving average price of $67.85 and a 200-day moving average price of $55.56. The firm has a market capitalization of $5.39 billion, a price-to-earnings ratio of -137.84 and a beta of 0.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.64 and a current ratio of 1.83.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.